Category Archives: Reagents

In the modern era of rituximab-based therapy as the first-line treatment, the prognoses of patients who require salvage therapy are poor and most will eventually succumb to their disease. this molecular era of disease definition will be the identification of combinations of novel brokers that target the oncogenic drivers of these subsets. Well-conducted clinical trials, with translational molecular investigations, will be essential to achieve the goal of precision medicine and expand the number of patients with DLBCL who achieve a cure. Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common B-cell non-Hodgkin lymphoma (NHL) throughout the world, comprising 30C35% of all NHLs.1 DLBCL is biologically aggressive, but can be cured in 50% of cases, even in advanced stages.2 However, up to one-third of patients have refractory disease or relapse after treatment.3 The standard salvage treatment for patients with relapsed or refractory DLBCL that remains sensitive to chemotherapy is autologous…

Read more